On Jul. 22, 2020, Oragenics announced that the National Institutes of Health created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the Company had generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19.

The NIHﾒs preclinical study shows that this spike protein, adjuvanted with the TLR-4-agonist Sigma Adjuvant System (a TLR-4 agonists that induces T cell activation), generates neutralizing antibody titers in both a pseudovirus neutralization assay and a plaque reduction neutralization titer (PRNT) assay.